Catalog No.
DVV00315
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG1, lambda2
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD
Concentration
2.52 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2-2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ADG-2, ADG-20 CAS: 2516243-54-0
Clone ID
Adintrevimab
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities., PMID:39126484
COVID-19 update: An EUA for pemivibart (Pemgarda) for pre-exposure prophylaxis., PMID:38696314
Emerging anti-spike monoclonal antibodies against SARS-CoV-2., PMID:38432691
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)., PMID:37496612
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron., PMID:37351456
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults., PMID:37185797
Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation., PMID:36975364
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers., PMID:36947596
Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19., PMID:36519929
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers., PMID:36299436
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies., PMID:35322239
For research use only. Not for human or drug use.
